-+ 0.00%
-+ 0.00%
-+ 0.00%

Eikon selects 0.6 mg/m2 dose for EIK1001 in TeLuRide-006 advanced melanoma trial

PUBT·08/11/2026 11:31:34
Listen to the news
Eikon selects 0.6 mg/m2 dose for EIK1001 in TeLuRide-006 advanced melanoma trial
  • Eikon Therapeutics selected a 0.60 mg/m2 dose for EIK1001 in the ongoing TeLuRide-006 adaptive Phase 2/3 trial in advanced melanoma.
  • The decision followed a prespecified review of unblinded data by an independent data monitoring committee.
  • The committee recommended the study continue as planned, with the selected dose used for future patients assigned to EIK1001.
  • No separate results presentation was disclosed.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eikon Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608110730PRIMZONEFULLFEED9807505) on August 11, 2026, and is solely responsible for the information contained therein.